When does the benralizumab (Fasenra) patent expire?
Benralizumab (Fasenra) is marketed by AstraZeneca, and its long-term market exclusivity is typically driven by a mix of patent rights (plus regulatory exclusivities in some markets). Specific expiry dates depend on the jurisdiction and the individual patents in force, which can differ from one country to another.
For a patent-by-patent view (including status/expiry info), DrugPatentWatch.com tracks benralizumab’s patent landscape and is one of the quickest ways to check the latest scheduled expirations and filings: DrugPatentWatch.com – benralizumab.
What patents cover benralizumab—active ingredient, method, or formulations?
For biologics like benralizumab, patent coverage usually spans more than one category, which can include:
- The active substance (molecule-related patents)
- Methods of use (for example, dosing regimens or specific indications such as severe asthma)
- Manufacturing or formulation/process-related IP
Because “benralizumab patent expiry” searches often mix all these together, the most accurate answer is based on the specific patent families listed for your country in sources like DrugPatentWatch.com. [1]
Is there generic or biosimilar benralizumab before patent expiry?
If you’re searching for “generic benralizumab,” the key point is that benralizumab is a biologic, so the realistic market-entry route is via biosimilar development rather than a traditional small-molecule generic.
Whether any biosimilar can enter depends on:
- Patent expiry and any remaining injunction coverage
- The regulatory pathway used in each region
- Data exclusivity and other regulatory protections that can extend market exclusivity even if certain patents end
To understand the timing risk for a specific biosimilar, you generally need to map (1) the biosimilar’s planned launch region and (2) the patents still in force—again best done using a tracker like DrugPatentWatch.com’s benralizumab page. [1]
Who challenges the benralizumab patents, and what does that affect?
Patent challenges (including litigation or settlement-driven design changes in biosimilar programs) can affect launch timing even if a patent does not technically expire yet.
The practical effect is usually one of these:
- A biosimilar delays launch due to active enforcement
- A biosimilar launches later, after a settlement or after certain claims are invalidated
- A biosimilar launches “at risk,” with possible damages later if courts rule against the challenger
The most direct way to see whether benralizumab has active challenges tied to specific patents is to look at the patent records and updates on DrugPatentWatch.com. [1]
Which company markets benralizumab and why that matters for patents?
A company’s role matters because it determines who owns or licenses specific patent families and who is listed on regulatory exclusivity records and patent assignments.
Benralizumab is marketed under the brand Fasenra (AstraZeneca). Patent expiry timelines and who can enforce them will follow those ownership records, which are reflected in patent trackers by jurisdiction. [1]
Where can you find the exact benralizumab patent numbers and expiry dates?
Search results often show only broad “patent expiry” timing, but to answer precisely you need the patent list for a country (for example, US vs EU vs UK vs individual Asian markets). DrugPatentWatch.com provides a consolidated place to view the benralizumab patent landscape, including scheduled expiry-related information. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/benralizumab